Infection and Chemotherapy最新文献

{"title":"Minocycline Susceptibility of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Blood Isolates from a Single Center in Korea: Role of <i>tetB</i> in Resistance.","authors":"Taeeun Kim, Eun Hee Jeon, Yoon-Kyoung Hong, Jiwon Jung, Min Jae Kim, Heungsup Sung, Mi-Na Kim, Sung-Han Kim, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim, Yong Pil Chong","doi":"10.3947/ic.2024.0110","DOIUrl":"10.3947/ic.2024.0110","url":null,"abstract":"<p><strong>Background: </strong>Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) represents a devastating and growing global threat, calling for new antibiotic treatments. In Korea, the challenge of treating CRAB is compounded by high nosocomial acquisition rates and limited availability of novel antibiotics. Minocycline, a semisynthetic tetracycline derivative, has been proposed as a therapeutic option for CRAB infections. Nonsusceptibility to minocycline may occur through the efflux pump, TetB. The prevalence of <i>tetB</i> in <i>A. baumannii</i> has increased, along with higher minocycline minimum inhibitory concentrations (MICs). We aimed to evaluate minocycline susceptibility rates in clinical strains of CRAB, and the association between <i>tetB</i> carriage and minocycline susceptibility across different genotypes.</p><p><strong>Materials and methods: </strong>Representative CRAB blood isolates were collected from Asan Medical Center, Seoul. Minocycline susceptibility was assessed using the Clinical and Laboratory Standards Institute (CLSI) breakpoint (≤4 mg/L) and the proposed pharmacokinetics (PK)/pharmacodynamics (PD) breakpoint (≤1 mg/L). Tigecycline was used as a comparator, and its susceptibility breakpoint for <i>Enterobacterales</i> defined by EUCAST was applied (≤0.5 mg/L). The presence of <i>tetB</i> was detected by PCR, and multilocus sequence typing (MLST) was performed using seven housekeeping genes.</p><p><strong>Results: </strong>Of the 160 CRAB blood isolates, 83.8% were susceptible to minocycline by the CLSI criteria, and 50.6% were PK-PD susceptible by the PK-PD criteria. The minocycline minimum inhibitory concentration (MIC)₅₀/MIC₉₀ was 1/8 mg/L. <i>tetB</i> was present in 49% of isolates and was associated with a higher minocycline MIC (MIC₅₀_/₉₀ 2/8 mg/L <i>vs.</i> 1/2 mg/L). No clear correlation was observed between <i>tetB</i> positivity and tigecycline MIC. Nine MLSTs were identified, with significant differences in <i>tetB</i> carriage rates between the major sequence types. Notably, ST191, associated with non<i>-tetB</i> carriage and greater susceptibility to minocycline, declined over the study period (<i>P</i>=0.004), while ST451, associated with <i>tetB</i> carriage, increased.</p><p><strong>Conclusion: </strong><i>tetB</i> was present in 49% of CRAB isolates and was associated with higher MICs and non-susceptibility by both CLSI and PK-PD criteria. However, absence of <i>tetB</i> was not a reliable predictor of minocycline PK-PD susceptibility. Additionally, shifts over time towards genotypes with reduced minocycline susceptibility were observed. Further research is needed to correlate these findings with clinical outcomes and identify additional resistance mechanisms.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"111-118"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Prevalence of Sequelae after COVID-19: A Longitudinal Cohort Study.","authors":"Se Ju Lee, Yae Jee Baek, Su Hwan Lee, Jung Ho Kim, Jin Young Ahn, Jooyun Kim, Ji Hoon Jeon, Hyeri Seok, Won Suk Choi, Dae Won Park, Yunsang Choi, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Jae-Hoon Ko, Kyong Ran Peck, Jae-Phil Choi, Jun Hyoung Kim, Hee-Sung Kim, Hye Won Jeong, Jun Yong Choi","doi":"10.3947/ic.2024.0090","DOIUrl":"10.3947/ic.2024.0090","url":null,"abstract":"<p><strong>Background: </strong>The World Health Organization has declared the end of the coronavirus disease 2019 (COVID-19) public health emergency. However, this did not indicate the end of COVID-19. Several months after the infection, numerous patients complain of respiratory or nonspecific symptoms; this condition is called long COVID. Even patients with mild COVID-19 can experience long COVID, thus the burden of long COVID remains considerable. Therefore, we conducted this study to comprehensively analyze the effects of long COVID using multi-faceted assessments.</p><p><strong>Materials and methods: </strong>We conducted a prospective cohort study involving patients diagnosed with COVID-19 between February 2020 and September 2021 in six tertiary hospitals in Korea. Patients were followed up at 1, 3, 6, 12, 18, and 24 months after discharge. Long COVID was defined as the persistence of three or more COVID-19-related symptoms. The primary outcome of this study was the prevalence of long COVID after the period of COVID-19.</p><p><strong>Results: </strong>During the study period, 290 patients were enrolled. Among them, 54.5 and 34.6% experienced long COVID within 6 months and after more than 18 months, respectively. Several patients showed abnormal results when tested for post-traumatic stress disorder (17.4%) and anxiety (31.9%) after 18 months. In patients who underwent follow-up chest computed tomography 18 months after COVID-19, abnormal findings remained at 51.9%. Males (odds ratio [OR], 0.17; 95% confidence interval [CI], 0.05-0.53; <i>P</i>=0.004) and elderly (OR, 1.04; 95% CI, 1.00-1.09; <i>P</i>=0.04) showed a significant association with long COVID after 12-18 months in a multivariable logistic regression analysis.</p><p><strong>Conclusion: </strong>Many patients still showed long COVID after 18 months post SARS-CoV-2 infection. When managing these patients, the assessment of multiple aspects is necessary.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"72-80"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis of <i>Pneumocystis jirovecii</i> Pneumonia in Non-HIV Immunocompromised Patient in Korea: A Review and Algorithm Proposed by Expert Consensus Group.","authors":"Raeseok Lee, Kyungmin Huh, Chang Kyung Kang, Yong Chan Kim, Jung Ho Kim, Hyungjin Kim, Jeong Su Park, Ji Young Park, Heungsup Sung, Jongtak Jung, Chung-Jong Kim, Kyoung-Ho Song","doi":"10.3947/ic.2024.0148","DOIUrl":"10.3947/ic.2024.0148","url":null,"abstract":"<p><p><i>Pneumocystis jirovecii</i> pneumonia (PJP) is a life-threatening infection commonly observed in immunocompromised patients, necessitating prompt diagnosis and treatment. This review evaluates the diagnostic performance of various tests used for PJP diagnosis through a comprehensive literature review. Additionally, we propose a diagnostic algorithm tailored to non-human immunodeficiency virus immunocompromised patients, considering the specific characteristics of current medical resources in Korea.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"45-62"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"End-of-Life Infections and the Dilemma of Emerging Antimicrobial Resistance: A Scoping Review.","authors":"Marwan Jabr Alwazzeh","doi":"10.3947/ic.2024.0088","DOIUrl":"10.3947/ic.2024.0088","url":null,"abstract":"<p><p>The goals of antimicrobial treatment of end-of-life (EOL) infections are variously defined, raising complex questions about the management futility, ethical aspects, psychosocial burden, and the risk of emerging antimicrobial resistance. The author searched PubMed, Scopus, and Web of Science databases to retrieve relevant articles published from May 1, 2000, to April 30, 2024, on EOL infections and emerging multidrug-resistant organisms. The titles and abstracts of retrieved articles were screened, duplicate records were excluded, and the eligibility of selected papers was assessed. Sixty-one articles were included; the prevalence of EOL infections and antimicrobial therapy were calculated, the common sites and characteristics of EOL infections were identified, and the extent of emerging multidrug-resistant organisms among EOL patients, especially the \"superbugs\" ones, were estimated. The review indicates that infections are common in terminally ill patients, the prevalence of irrational antimicrobial prescriptions is high globally, with antimicrobials frequently administered until death. Limited data regarding antimicrobial resistance are available, and they cover short periods, while many of those patients survive longer with modern healthcare and become an essential reservoir for emerging multidrug-resistant organisms. This underscores the importance of antimicrobial stewardship programs and the urgent need for further research in this often-overlooked study area.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"1-12"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Pseudomonas aeruginosa</i> in Chronic Suppurative Otitis Media.","authors":"Artono Artono, Nyilo Purnami, Edi Handoko, Agung Dwi Wahyu Widodo, Juniastuti Juniastuti","doi":"10.3947/ic.2024.0062","DOIUrl":"10.3947/ic.2024.0062","url":null,"abstract":"<p><strong>Background: </strong>Chronic suppurative otitis media (CSOM) has caused many hearing disorder cases in developing countries. Inappropriate antibiotic use resulted in a shift of bacterial resistance. The biofilm-forming bacteria, like <i>Pseudomonas aeruginosa</i>, was a common germ detected in CSOM that contributed to a poor prognosis. This study aimed to investigate the bacterial pattern from samples taken from CSOM patients regarding its antibiotic susceptibility and the antibiofilm activity of acetic acid against <i>P.</i> aeruginosa.</p><p><strong>Materials and methods: </strong>Sterile swabs of forty-five patients with CSOM were collected, followed by isolation of bacterial pathogens, identification, and evaluation of antibiotic sensitivity using modified Kirby Bauer disc diffusion protocol. <i>In vitro</i> testing was done by adding acetic acid to <i>P. aeruginosa</i> culture to gauge the minimum concentration of biofilm inhibition and eradication. They were conducted using the microtiter plate assay method and quantified with an ELISA reader. The data were analyzed statistically using One-Way ANOVA and Tukey Honestly Significant Difference post hoc test.</p><p><strong>Results: </strong>The samples obtained from 31 of 45 CSOM patients showed positive microbial growth; 26 (57.78%) had a monomicrobial pattern, and 5 (11.11%) had a polymicrobial pattern. The researcher ascertained that 24 isolates, representing 66.67%, were gram-negative bacteria, with <i>P.-aeruginosa</i> identified as the predominant species. <i>P. aeruginosa</i> isolates were sensitive to several antibiotics, including meropenem, amikacin, piperacillin-tazobactam, ceftazidime, and cefoperazone-sulbactam with a rate of 93.33%. The minimum concentration of acetic acid required to qualify as the minimum biofilm inhibitory concentration (MBIC) was determined to be 0.16%, yielding an inhibition rate of 26.79%. A concentration of 0.31% was identified as the minimum biofilm eradication concentration (MBEC), achieving an eradication rate of 77.27%.</p><p><strong>Conclusion: </strong><i>P. aeruginosa</i>, the most common bacteria found in CSOM samples, was sensitive to imipenem, amikacin, piperacillin-tazobactam, ceftazidime, and cefoperazone-sulbactam. Acetic acid suppresses <i>P. aeruginosa</i> bacterial biofilm formation at MBIC of 0.16% and MBEC of 0.31%.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"63-71"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Should Cytomegalovirus Infection Be Managed in Allogeneic Hematopoietic Stem Cell Transplant Recipients? A Clinical Grand Round.","authors":"Dukhee Nho, Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee","doi":"10.3947/ic.2024.0140","DOIUrl":"10.3947/ic.2024.0140","url":null,"abstract":"<p><p>Cytomegalovirus (CMV) is a significant concern for patients with allogeneic hematopoietic cell transplantation (allo-HCT). CMV management differs between institutions due to the lack of local guidelines. Here, we describe a case of refractory/resistant CMV infection treated using our institution's CMV management protocol. A 59-year-old woman who underwent allo-HCT was treated for CMV reactivation. Despite 3 months of valganciclovir administration, serum CMV level surged. CMV gene mutation test revealed a ganciclovir-resistant A594V mutation in the <i>UL97</i> gene. Treatment was switched to foscarnet until the drug became unavailable nationwide. During the foscarnet shortage, cidofovir was used, leading to a decline in CMV levels when foscarnet was reintroduced and used for 2 months. Following allo-HCT, CMV prophylaxis with letermovir is crucial to prevent reactivation in seropositive recipients. CMV titers should be monitored frequently after allo-HCT. The cutoff value for preemptive therapy varies across institutions, with ganciclovir/valganciclovir usually administered as first-line therapy. Maribavir is an option in cases of ganciclovir/valganciclovir resistance or intolerance. CMV gene mutations should be examined in patients with suspected resistance after 2 weeks of appropriate treatment. This case was discussed at the Clinical Grand Round of the Annual Conference of the Korean Society of Infectious Diseases on November 2, 2023.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"38-44"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unveiling the Outcomes of Mpox in Pregnancy: A Systematic Review and Single-Arm Meta-Analysis.","authors":"I Gde Sastra Winata, Leonardo Leonardo, Rosalia Sylfiasari, Angeline Ekafentie, Surya Sinaga Immanuel, Fenyta Christyani","doi":"10.3947/ic.2024.0120","DOIUrl":"10.3947/ic.2024.0120","url":null,"abstract":"<p><strong>Background: </strong>The global resurgence of mpox, formerly monkeypox, poses an emerging threat to pregnant women due to immunological changes and potential vertical transmission, yet its impact on pregnancy remains underexplored. This study aims to pioneer a comprehensive assessment of pregnancy outcomes and the risks of vertical transmission associated with mpox infection during pregnancy.</p><p><strong>Materials and methods: </strong>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we searched three databases up to September 2024 for studies on pregnant women with mpox confirmed by quantitative polymerase chain reaction. Primary outcomes were composite adverse pregnancy outcomes: miscarriage or fetal death, congenital anomalies, and chorioamnionitis; the secondary outcome was vertical transmission. Study quality was assessed using Joanna Briggs Institute tools. Statistical analysis employed R software using a one-proportion model with Freeman-Tukey transformation and random-effects meta-analysis (restricted maximum-likelihood estimator, Knapp-Hartung adjustment), presenting estimated proportions with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Six studies (three case series, three case reports) comprising 11 singleton pregnancies were included. Diagnoses occurred in the first (27.3%), second (45.4%), and third trimesters (27.3%). Among the five genotypically identified Mpox cases, 20.0% were classified Clade I and 80.0% as Clade II. Meta-analysis indicated that an estimated 63% (95% CI, 43-83%) of pregnancies experienced composite adverse pregnancy outcomes. Specifically, miscarriage or fetal death occurred in 62% (95% CI, 21-102%), congenital anomalies in 50% (95% CI, 21-80%), and chorioamnionitis in 78% (95% CI, 44-96%). Vertical transmission was observed in 79% (95% CI, 6-151%). Despite small sample sizes leading to wide confidence intervals, high estimated proportions suggest that mpox severely impacts pregnancy outcomes, likely linked to maternal inflammation, placental invasion, and significant fetal risks from vertical transmission.</p><p><strong>Conclusion: </strong>Mpox infection during pregnancy appears to be associated with high rates of adverse pregnancy outcomes and vertical transmission. Further large-scale studies are warranted to confirm these findings and develop preventive and management strategies mitigating this emerging threat.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"119-130"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food, Water, Air, and Mind must Become Cleaner.","authors":"Josef Finsterer, Carla Alexandra Scorza, Fulvio Alexandre Scorza, Ana Claudia Fiorini","doi":"10.3947/ic.2024.0136","DOIUrl":"10.3947/ic.2024.0136","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"181-182"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Determinants of Carbapenem and Fluoroquinolone Resistance in <i>Escherichia coli</i> Isolates of Clinical Origin.","authors":"Simbiat Tolani Lawal, Fadilulahi Ayokunle Usman, Zainab Adepeju Adams, Omoladun Safurat Ogunbayo, Chioma Margaret Ekwedigwe, Rukayat Olajumoke Jimoh, Fortunate Opeyemi Oladeru, Oyindamola Osho, Utibeima Udo Essiet, Abraham Ajayi, Stella Smith","doi":"10.3947/ic.2024.0108","DOIUrl":"10.3947/ic.2024.0108","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance has emerged as a global public health challenge, leading to higher mortality rates from infections that were once treatable with antibiotics. In this study, we assessed the susceptibility of <i>Escherichia coli</i> strains isolated from clinical samples to carbapenems and fluoroquinolones and screened for genetic determinants mediating resistance.</p><p><strong>Materials and methods: </strong>This retrospective study included 46 <i>E. coli</i> isolates retrieved from the stock culture collection at the Molecular Biology and Biotechnology Department of the Nigerian Institute of Medical Research. Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc diffusion method, and molecular techniques were employed to detect genetic determinants of antimicrobial resistance.</p><p><strong>Results: </strong>The <i>E. coli</i> isolates exhibited high resistance to fluoroquinolones, with 72% resistant to ciprofloxacin and 52% to levofloxacin. Resistance to carbapenems was relatively low, with 4% resistant to imipenem and 11% to meropenem. The prevalence of the genetic determinants <i>gyrA</i>, <i>gyrB</i>, and <i>parC</i>, which mediate fluoroquinolone resistance, was 26%, 24%, and 15%, respectively. <i>bla</i>_OXA-48 and <i>bla</i>_NDM, which mediate carbapenem resistance, were detected in only two isolates. Some isolates harbored plasmids ranging from 5 kb to 16 kb; however, no plasmid-mediated genetic determinants conferring fluoroquinolone resistance were identified.</p><p><strong>Conclusion: </strong>This study revealed a high level of resistance to fluoroquinolones, emphasizing the need for judicious use of antibiotics, particularly those with low resistance rates. Continuous surveillance is essential to monitor emerging trends in resistance among bacterial pathogens.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"57 1","pages":"102-110"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus Retinitis in a Hematopoietic Stem Cell Transplant Recipient During Maribavir Pre-emptive Therapy.","authors":"Hyeon Mu Jang, Han-Seung Park, Heungsup Sung, Sung-Han Kim","doi":"10.3947/ic.2024.0131","DOIUrl":"10.3947/ic.2024.0131","url":null,"abstract":"<p><p>We report a case of cytomegalovirus retinitis in a hematopoietic stem cell transplant recipient during valganciclovir pre-emptive therapy followed by maribavir. Analysis of UL97 mutation revealed a C480F substitution associated with high maribavir resistance and low ganciclovir resistance.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"168-171"},"PeriodicalIF":2.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}